79 related articles for article (PubMed ID: 20634188)
1. Up-regulation of apoptosis by gonadotrophin-releasing hormone agonist in cultures of endometrial cells from women with symptomatic myomas.
Kang JL; Wang DY; Wang XX; Yu J
Hum Reprod; 2010 Sep; 25(9):2270-5. PubMed ID: 20634188
[TBL] [Abstract][Full Text] [Related]
2. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
3. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
Zhao LJ; Wei LH; Li XP; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
Wang Y; Matsuo H; Kurachi O; Maruo T
Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
6. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
7. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
8. Phosphatase and tensin homolog gene inhibits the effect induced by gonadotropin-releasing hormone subtypes in human endometrial carcinoma cells.
Zhao LJ; Liu N; Li XP; Wang JL; Wei LH
Chin Med J (Engl); 2010 May; 123(9):1170-5. PubMed ID: 20529558
[TBL] [Abstract][Full Text] [Related]
9. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Fister S; Günthert AR; Aicher B; Paulini KW; Emons G; Gründker C
Cancer Res; 2009 Aug; 69(16):6473-81. PubMed ID: 19638591
[TBL] [Abstract][Full Text] [Related]
10. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
[TBL] [Abstract][Full Text] [Related]
11. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
12. Effect of gonadotropin-releasing hormone analogs and their conjugates on gonadotropin-releasing hormone receptor--positive human cancer cell lines.
Pályi I; Vincze B; Kálnay A; Turi G; Mezõ I; Teplán I; Seprõdi J; Pató J; Móra M
Cancer Detect Prev; 1996; 20(2):146-52. PubMed ID: 8706040
[TBL] [Abstract][Full Text] [Related]
13. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
Günthert AR; Gründker C; Hollmann K; Emons G
Biochem Biophys Res Commun; 2002 May; 294(1):11-5. PubMed ID: 12054733
[TBL] [Abstract][Full Text] [Related]
14. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line.
Shibata S; Sato H; Ota H; Karube A; Takahashi O; Tanaka T
Gynecol Oncol; 1997 Aug; 66(2):217-21. PubMed ID: 9264565
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
16. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen modulates apoptotic pathways in primary endometrial cell cultures.
Stackievicz R; Drucker L; Radnay J; Beyth Y; Yarkoni S; Cohen I
Clin Cancer Res; 2001 Feb; 7(2):415-20. PubMed ID: 11234898
[TBL] [Abstract][Full Text] [Related]
18. Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: relationship between clinical features and immunohistochemical changes.
De Falco M; Staibano S; Mascolo M; Mignogna C; Improda L; Ciociola F; Carbone IF; Di Lieto A
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):44-7. PubMed ID: 19297072
[TBL] [Abstract][Full Text] [Related]
19. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
20. Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue.
Burke C; Hickey K
Obstet Gynecol; 2004 Nov; 104(5 Pt 2):1182-4. PubMed ID: 15516445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
